Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Convertible Debt (2016 - 2017)

STRATA Skin Sciences' Convertible Debt history spans 4 years, with the latest figure at $13.4 million for Q2 2017.

  • On a quarterly basis, Convertible Debt rose 23.67% to $13.4 million in Q2 2017 year-over-year; TTM through Jun 2017 was $13.4 million, a 23.67% increase, with the full-year FY2016 number at $12.0 million, up 22.25% from a year prior.
  • Convertible Debt hit $13.4 million in Q2 2017 for STRATA Skin Sciences, up from $12.7 million in the prior quarter.
  • Over the last five years, Convertible Debt for SSKN hit a ceiling of $13.4 million in Q2 2017 and a floor of $5.0 million in Q4 2014.
  • Historically, Convertible Debt has averaged $9.9 million across 4 years, with a median of $10.8 million in 2016.
  • Biggest five-year swings in Convertible Debt: skyrocketed 125.99% in 2015 and later grew 0.22% in 2016.
  • Tracing SSKN's Convertible Debt over 4 years: stood at $5.0 million in 2014, then surged by 96.74% to $9.8 million in 2015, then rose by 22.25% to $12.0 million in 2016, then rose by 11.29% to $13.4 million in 2017.
  • Business Quant data shows Convertible Debt for SSKN at $13.4 million in Q2 2017, $12.7 million in Q1 2017, and $12.0 million in Q4 2016.